Bevacizumab in non-small cell lung cancer: new indication. Too many adverse effects to justify its use.

首页> 外文期刊>Prescrire international >Bevacizumab in non-small cell lung cancer: new indication. Too many adverse effects to justify its use.

【24h】

Bevacizumab in non-small cell lung cancer: new indication. Too many adverse effects to justify its use.

机译：贝伐单抗用于非小细胞肺癌的新适应症。太多的不良影响无法证明其用途。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The numerous adverse effects (especially life-threatening infections and bleeding) outweigh the at best only moderate efficacy.

机译：众多的不利影响（尤其是威胁生命的感染和出血）最多只能起到中等程度的疗效。

著录项

来源
《Prescrire international》 |2009年第99期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Bevacizumab in non-small cell lung cancer: new indication. Too many adverse effects to justify its use. [J] . Prescrire international . 2009,第99期

机译：贝伐单抗用于非小细胞肺癌的新适应症。太多的不良影响无法证明其用途。
2. Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients [J] . de Goeje Pauline L., Poncin Myrthe, Bezemer Koen, Clinical cancer research: an official journal of the American Association for Cancer Research . 2019,第7期

机译：通过紫杉醇，卡铂和贝伐单抗在非小细胞肺癌患者中组合诱导外周效应CD8 T细胞增殖
3. Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG) [J] . Kotsakis A., Kentepozidis N., Emmanouilidis Ch., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2015,第1期

机译：相较于多西他赛加顺铂和贝伐单抗方案，长春瑞滨加顺铂和贝伐单抗，多西他赛加吉西他滨和贝伐单抗的序贯给药作为晚期或转移性非鳞状非小细胞肺癌一线治疗的多西他赛方案希腊肿瘤研究小组（HORG）
4. EFFECTS OF CARVACROL ON A HUMAN NON-SMALL CELL LUNG CANCER (NSCLC) CELL LTNE, A549 [C] . A.Tansu Koparal, Melih Zeytinoglu Annual Meeting of the Japanese Association for Animal Cell Technology . 2003

机译：Carvacrol对人非小细胞肺癌（NSCLC）细胞LTNE，A549的影响
5. Effects of TNFAIP8 knockdown on EGFR and IGF-1R signaling and cytotoxicities of targeted drugs in non-small cell lung cancer cells [D] . Day, Timothy Francis 2015

机译：TNFAIP8组合对非小细胞肺癌细胞EGFR和IGF-1R信号传导及靶向药物的细胞毒性的影响
6. Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable non-squamous non-small cell lung cancers [O] . Jamie E. Chaft, Valerie Rusch, Michelle S. Ginsberg, -1

机译：新辅助贝伐单抗联合化疗和贝伐单抗在可切除的非鳞状非小细胞肺癌患者中的II期试验
7. Adverse Events Related to Bevacizumab and the Management Principles in Non-small Cell Lung Cancer [O] . Gang CHENG, Li ZHANG 2010

机译：贝伐单抗相关不良事件及非小细胞肺癌的治疗原则

Bevacizumab in non-small cell lung cancer: new indication. Too many adverse effects to justify its use.

摘要

著录项

相似文献

相关主题

期刊订阅